SI-BONE, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 08, 2023 at 01:40 am IST
Share
SI-BONE, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 33.31 million compared to USD 25.59 million a year ago. Net loss was USD 11.21 million compared to USD 18.51 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 0.54 a year ago. Diluted loss per share from continuing operations was USD 0.3 compared to USD 0.54 a year ago.
For the six months, sales was USD 66.01 million compared to USD 48.02 million a year ago. Net loss was USD 22.33 million compared to USD 35.92 million a year ago. Basic loss per share from continuing operations was USD 0.61 compared to USD 1.06 a year ago.
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
SI-BONE, INC. 
